JPJan B. Pietzsch

Jan B. Pietzsch

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jan B. Pietzsch has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Value-Based Care: A Review of Key Challenges and Opportunities Relevant to Medical Technology Innovators

    by Véronique Peiffer, Cynthia A. Yock, Paul G. Yock, Jan B. Pietzsch

    Developed countries struggle with high healthcare spending, and cost is often cited as a barrier to the introduction of new patient care technologies. The core objective of this review article is to help familiarize medical technology innovators with trends in the health economic environment and the implications for the adoption of new technologies. We review and discuss this topic in language accessible to medical technology innovators. We assess macrolevel developments in healthcare spending and highlight measures already taken to control spending. We discuss practical implications for anyone involved in healthcare innovation. Two observations are central to this discussion: (1) the U.S. spends significantly more on healthcare per capita than any other developed country; (2) across developed countries, healthcare spending has risen steadily over the past two decades. Nevertheless, higher spending has not always led to improvements in health. As a result, innovators need to be prepared to navigate an outcomes-oriented and value-based environment that is being defined by the emerging requirements of various healthcare stakeholders. Practically, new products should aim to improve health outcomes at a cost deemed “good value” and/or reduce cost for one or multiple stakeholders. Opportunities also exist for tools that enable cost/outcomes tracking, which will help demonstrate value to providers, insurers, and patients.


  • Early technology assessment of new medical devices

    by Jan B. Pietzsch, M. Elisabeth Paté-Cornell

    Objectives: In the United States, medical devices represent an eighty-billion dollar a year market. The U.S. Food and Drug Administration rejects a significant number of applications of devices that reach the investigational stage. The prospects of improving patient condition, as well as firms' profits, are thus substantial, but fraught with uncertainties at the time when investments and design decisions are made. This study presents a quantitative model focused on the risk aspects of early technology assessment, designed to support the decisions of medical device firms in the investment and development stages. Methods: The model is based on the engineering risk analysis method involving systems analysis and probability. It assumes use of all evidence available (both direct and indirect) and integrates the information through a linear formula of aggregation of probability distributions. The model is illustrated by a schematic version of the case of the AtrialShaper, a device for the reduction of stroke risk that is currently in the preprototype stage. Results: The results of the modeling provide a more complete description of the evidence base available to support early-stage decisions, thus allowing comparison of alternative designs and management alternatives. Conclusions: The model presented here provides early-stage decision-support to industry, but also benefits regulators and payers in their later assessment of new devices and associated procedures.


    • 1 April 2001
      • Vol. 46  (4) , 96-100

    [Conditions and success factors of telemedicine innovation].

    by J B Pietzsch, H G Gemuenden, A Bolz

    Telemedicine and health telematics can play a significant role in improving the efficiency of health care systems. Currently, however, the potential of telemedical applications is far from being fully utilized. In the present study, an attempt has been made to identify factors that may aid the further dissemination and general acceptance of telemedical innovations. The results obtained suggest that apart from the factors under the sole control of legislation, and insurance providers, those that can be directly influenced by developers, manufacturers and providers of telemedical applications play an important role. Of particular importance for the successful and lasting use of such applications is the creation of promising business models, aspects of which are considered in the last part of the article.